Swedish medical technology company Coala Life's heart monitor enables patient- and user-centered cardiac monitoring. The system is based on an adhesive-free sensor that the patient carries and an algorithm-loaded app.

The heart monitoring system was approved by the FDA in February, 2019. The estimated U.S. market value of the monitoring of heart rhythm disorders was $2 billion in 2017, according to the company, partly because the FDA actively promotes the introduction of digital healthcare.


Over 100 million Americans are suffering from high blood pressure, a risk factor that increases the risk of atrial fibrillation and stroke. Almost 10 percent of all Americans over the age of 65 are estimated to be afflicted with atrial fibrillation and even more of other heart rhythm disorders, many without knowing it. Just under 200 healthcare providers are today affiliated with Coala Life's platform in Sweden and just over half a million ECG analyzes have been carried out with the system. Cardiac arrhythmias and atrial fibrillation are detected and diagnosed with ECG.

For more info, see www.coalalife.com